The 7-year follow-up of TAVR versus surgery in low-risk aortic stenosis patients showed durable outcomes for transcatheter intervention, with mortality and stroke rates remaining comparable to surgical aortic valve replacement. These long-term data support TAVR as a viable option across the full surgical risk spectrum.
New England Journal of Medicine, Volume 394, Issue 8, Page 773-783, February 19, 2026.
